首页>
外国专利>
Prediction, diagnosis and treatment of endocrine resistant breast cancer, using p38 mapk pathway
Prediction, diagnosis and treatment of endocrine resistant breast cancer, using p38 mapk pathway
展开▼
机译:p38 mapk途径对内分泌耐药性乳腺癌的预测,诊断和治疗
展开▼
页面导航
摘要
著录项
相似文献
摘要
Acquired and de novo endocrine resistance are major clinical problems in the management of breast cancer patients. Though the antiestrogen tamoxifen prolongs disease-free and overall survival in the adjuvant setting, and induces remissions in over half of the patients with estrogen receptor positive metastatic disease, all patients eventually acquire tamoxifen resistance. Furthermore, many of the resistant tumors actually appear to be stimulated by tamoxifen just as they are by estrogens. The present invention provides methods of predicting endocrine resistance comprising detecting the biological activity and/or expression of p38 MAPK and/or AIB1. The invention further provides methods of reducing, reversing, or preventing endocrine resistance comprising contacting a breast or prostate tumor with a p38 MAPK pathway inhibitor.
展开▼